Download presentation
Presentation is loading. Please wait.
Published byAda Kokkonen Modified over 5 years ago
1
Longitudinal analysis of ZIKV E–specific memory B cell responses in the DENV-experienced donors.
Longitudinal analysis of ZIKV E–specific memory B cell responses in the DENV-experienced donors. (A) ZIKV E–specific memory B cell sorting. Fluorescence-activated cell sorting (FACS) plots show ZIKV E reactivity of IgG+ B cells from the three convalescent DENV-experienced donors and a ZIKV seronegative healthy donor control. B cells in quadrant 2 (Q2) were single cell–sorted for mAb cloning. ZIKV E was labeled with two different colors to reduce background binding. (B) Apparent binding affinities of plasmablast and memory B cell–derived mAbs to recombinant ZIKV E. Red bars indicate the median IC50s. (C) Clonal lineage analysis of memory B cell–derived mAbs. Heavy-chain sequences were assigned to lineages using Clonify (52). Each lineage is represented as a segment proportional to the lineage size. The total number of recovered heavy chains is shown in the center of each pie. All lineages that contain only a single sequence are combined and shown as a single gray segment. (D) Heat map showing apparent binding affinities of the memory B cell–derived mAbs to recombinant ZIKV E and DENV1–4 E proteins. Top: mAbs cloned from donor 3. Bottom: mAbs cloned from donor , ADI competitor; 056, ADI competitor; 314, ADI competitor; 247, ADI competitor; FL, 4G2 competitor; DIII, recombinant DIII binder; UK, unknown. (E) Load of somatic mutations (expressed as the number of nucleotide substitutions in the VH) in mAbs isolated from plasmablasts and memory B cells in DENV-experienced donors. Each point represents an individual mAb. Red bars indicate the median number of nucleotide substitutions. (F) Binding of plasmablast and memory B cell–derived mAbs to recombinant ZIKV E. Apparent binding affinities are shown in the plot. Red bars indicate median apparent IC50s. Statistical comparisons were made using Mann-Whitney test (***P < 0.001, **P < 0.01; n.s., not significant). Thomas F. Rogers et al. Sci. Immunol. 2017;2:eaan6809 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.